There is currently no effective medical therapy for men with infertility due to oligoasthenozoospermia. As men with abnormal sperm production have lower concentrations of 13-cis-retinoic acid in their testes, we hypothesized that men with infertility from oligoasthenozoospermia might have improved sperm counts when treated with isotretinoin (13-cis-retinoic acid). We conducted a single-site, single-arm, pilot study to determine the effect of therapy with isotretinoin on sperm indices in 19 infertile men with oligoasthenozoospermia. Subjects were men between 21 and 60 years of age with infertility for longer than 12 months associated with sperm concentrations below 15 million sperm/mL. All men received isotretinoin 20 mg by mouth twice daily for 20 weeks. Subjects had semen analyses, physical examinations, and laboratory tests every 4 weeks during treatment. Nineteen men enrolled in the study. Median (25th, 75th) sperm concentration increased from 2.5 (0.1, 5.9) million/mL at baseline to 3.8 (2.1, 13.0) million/mL at the end of treatment (p = 0.006). No significant changes in sperm motility were observed. There was a trend toward improved sperm morphology (p = 0.056). Six pregnancies (three spontaneous and three from intracytoplasmic sperm injection) and five births occurred during the study. Four of the births, including all three of the spontaneous pregnancies, were observed in men with improvements in sperm counts with isotretinoin therapy. Treatment was well tolerated. Isotretinoin therapy improves sperm production in some men with oligoasthenozoospermia. Additional studies of isotretinoin in men with infertility from oligoasthenozoospermia are warranted.
INTRODUCTION
Infertility affects 10-15% of couples attempting to conceive, with roughly one million couples seeking medical assistance for infertility yearly in the USA (Chandra et al., 2013) . Infertility attributable to the male partner accounts for 40% of infertility, and the most common forms of male infertility involve impairments in sperm production (Jequier & Holmes, 1993) . Unfortunately, 75% of men with infertility from oligoasthenozoospermia (OA) do not have a medically or surgically treatable cause (Punab et al., 2017; ) . In such men, in vitro fertilization coupled with intracytoplasmic sperm injection (ICSI) can treat infertility (Schlegel, 2009) ; however, these procedures are expensive and unsuccessful in some cases. Therefore, new approaches to the treatment of infertility in men with OA are needed.
For almost a century, it has been known that vitamin A deficiency causes male infertility due to impaired sperm production (Wolbach & Howe, 1925) . Vitamin A is converted to its active form, retinoic acid, in the testes via the activity of retinol and retinal dehydrogenases (Napoli, 1996) . In vitamin A/retinoic acid-deficient rodents, the conversion of undifferentiated to differentiating spermatogonia is arrested, and resupplementation with vitamin A or retinoic acid restores spermatogenesis and fertility (Van Pelt & de Rooij, 1990 , 1991 . The effects of vitamin A on spermatogenesis are dependent on retinoic acid receptors (Doyle et al., 2007; Anderson et al., 2008; Chung et al., 2009) , and genetic deletion of these receptors in mice results in sterility secondary to impaired sperm production Lufkin et al., 1993; Kastner et al., 1996; Ghyselinck et al., 2006) . Similarly, pharmacological inhibition of retinoic acid biosynthesis (Amory et al., 2011; Paik et al., 2014) , or blockade of retinoic acid receptors (Schulze et al., 2001; Chung et al., 2011) , suppresses sperm production in animals.
To understand the relationship between intratesticular retinoic acid and sperm production in man, we measured tissue concentrations of all-trans and 13-cis-retinoic acid in testicular tissue from 24 men undergoing scrotal surgery and found that concentrations of 13-cis-retinoic acid were significantly reduced in the men with abnormal sperm production (Nya-Ngatchou et al., 2013) . This finding suggested that some men with infertility might have reduced concentrations of retinoic acid in their testes, possibly due to deficient biosynthesis. Indeed, follow-up work demonstrated that men presenting with infertility had significantly reduced levels of ALDH1A2, an enzyme that produces retinoic acid, in their testes compared to fertile men . If some men with infertility have reduced concentrations of intratesticular retinoic acid, treatment with retinoic acid might improve their sperm output and their fertility.
The medical literature supports the notion that the administration of 13-cis-retinoic acid is beneficial for sperm production. Four cohort studies, enrolling a total of 126 normal men being treated with isotretinoin for acne, have examined the effects of 13-cis-retinoic acid/isotretinoin on sperm production (Vogt & Ewers, 1985; Torok et al., 1987; Hoting et al., 1992; C ß inar et al., 2016) . Unexpectedly, men in the three of the studies exhibited significant improvements in their sperm counts during treatment. Unfortunately, these observations were not widely recognized, and isotretinoin was never tested as a possible treatment for male infertility.
Oral 13-cis-retinoic acid in the form of isotretinoin is currently approved for the treatment of acne and other dermatological conditions, and its dosing and side effect profile are well-known (Kerr et al., 1982; Brazzell et al., 1983; Biesalski, 1989; Muindi et al., 2008) . To determine the effect of isotretinoin on sperm production in men with infertility, we conducted a single-arm pilot study in nineteen men with infertility from oligoasthenozoospermia (OA). We hypothesized that treatment with isotretinoin for twenty weeks would improve sperm production in these men.
MATERIALS AND METHODS

Subjects and study design
As isotretinoin had not previously been studied for the treatment of male infertility, we opted for a simple, single-arm pilot study design with the subject's baseline semen analyses serving as their own controls. The subjects were infertile men between 21 and 60 years of age with a sperm concentration of less than 15 million/mL on two baseline samples and more than twelve months of infertility. Men were recruited from Seattle area infertility clinics using informational flyers and were reimbursed for expenses related to study participation. Exclusion criteria included the following: genetic causes of infertility (e.g., Klinefelter's or Y chromosome microdeletions), hypogonadotropic hypogonadism, the use of anabolic steroids or illicit drugs within the last 12 months, consumption of more than four alcoholic beverages daily, use of illicit drugs, therapy with isotretinoin or all-trans-retinoic acid in the last 12 months, severe mental health problems requiring medications, a score of greater than 15 on the Patient Health Questionnaire-9 (PHQ-9) questionnaire, abnormal serum chemistry values according to our laboratory normal values indicative of liver or kidney dysfunction, current therapy with tetracycline, phenytoin, rifampin, phenobarbital, highly active antiretroviral therapy or other inducers of CYP enzymes, infection with HIV, a history of inflammatory bowel disease, or fasting serum triglycerides of greater than 500 mg/dL. This study was approved by the Institutional Review Board of the University of Washington and conducted under IND#120703 from the US FDA and registered on clinicaltrials.gov as trial #NCT02061384: 'A Pilot Trial of 13-cisretinoic acid (Isotretinoin) for the Treatment of Men With Oligoasthenoteratozoospermia' prior to any study procedures.
Procedures
Prior to participation, subjects signed an Institutional Review Board approved informed consent document. At each study visit, an examination and vital signs were performed. In addition, a blood sample was obtained for the blood counts, serum chemistries and fasting lipids, testosterone, LH, FSH, and retinoic acid after an overnight fast. In addition, subjects completed the PHQ-9 depression questionnaire at each visit. For assessment of spermatogenesis, subjects provided two baseline semen samples after 48 h of abstinence and at least one week apart to confirm the diagnosis of idiopathic oligoasthenozoospermia (OA). They also provided a third semen sample prior to starting therapy and every 4 weeks during the twenty-week treatment phase, as well as 4, 12, and 24 weeks after completing therapy. During the treatment phase, subjects were prescribed isotretinoin at a dose of 20 mg twice daily for 20 weeks (the dose prescribed for acne treatment). Subjects were not blinded to the results of their semen analyses. Subjects eleven through nineteen also received calcitriol at a dose of 0.25 lg twice daily to see whether this would improve sperm motility or have an additive effect on sperm production. Medication compliance was monitored by self-reported subject logs and pill counts of returned medication. In addition, subjects were assessed for side effects at each clinic visit. Serum samples for measurements of retinoic acid were collected before the morning dose. Blood was collected into vacutainers wrapped in aluminum foil to prevent light exposure that could degrade retinoic acid and allowed to clot for 30 min at room temperature before centrifugation at 1000-2000 g for 15 min. Following centrifugation, the serum samples were decanted and frozen in light-protected vials at À80°C until analysis. Semen samples and seminal plasma samples were similarly light protected.
Measurements
Semen samples were allowed to liquefy for 30-60 min at 37°C and then analyzed for sperm concentration, count, and motility within 60 min of liquefaction using the WHO protocol (WHO, 2010) . Sperm morphology was assessed using the 'strict' WHO criteria. Specifically, semen was allowed to liquefy for 20-30 min at 37°C; volume, pH, viscosity, and liquefaction were measured, and samples were then analyzed for sperm concentration, count, and motility within 10-20 min of liquefaction using the 5th edition WHO protocol (WHO, 2010) . Sperm morphology was assessed using 'strict morphology' WHO criteria. Sperm motility was assessed by phase-contrast wet mount, accounting for overall % motility, % progressive motility, and % rapid linear motility of at least 100 and typically 200 spermatozoa. When needed due to low sperm concentration, semen was diluted no more than 1 : 1 in Hepes, gently centrifuged at 250 g for 7 min, and supernatant was removed to leave 50-100 lL which was thoroughly 1116 Andrology, 2017, 5, 1115-1123 mixed prior to motility analysis and concentration assessment. For sperm concentration, 10 or 20 lL of semen or concentrated spermatozoa was measured by positive displacement pipette and diluted with a known volume of distilled water to inhibit motility. Sperm concentration was measured in Improved Neubauer Phase hemocytometer (Hausser Scientific Co., Horsham, PA) after correcting for centrifugal concentration and dilution. Blood counts and serum chemistry and hormone tests were performed by the clinical laboratory at the University of Washington.
Retinoid concentrations were measured as described previously (Arnold et al., 2012) . Specifically, serum 13-cis, all-trans, and 4-oxo-13-cis-retinoic acid concentrations were measured using an AB Sciex (Framingham, MA) qTrap 5500 mass spectrometer equipped with an Agilent Technologies (Santa Clara, CA) 1290 Infinity ultrahigh pressure liquid chromatography system as described previously. Deuterated (d) compounds were used as internal standards. To prepare samples for analysis, 80 lL of 250 nM 13-cis-retinoic acid-d5, 500 nM 4-oxo-alltrans-retinoic acid-d3, and 100 nM all-trans-retinoic acid-d5 was added as internal standards in acetonitrile to 80 lL of the samples. Samples were then centrifuged twice at 3000 g for 10 min at 4°C, and the supernatant was collected for quantification. Retinoic acid concentrations in seminal plasma were measured using an AB Sciex (Framingham, MA) qTrap 6500 mass spectrometer coupled to a Shimadzu (Kyoto, Japan) LC-20AD liquid chromatography system using the approach described above. Retinoic acid species were separated with an Ascentis â Express RP-Amide 15 cm 9 2.1 mm, 2.7 lm column (Sigma-Aldrich, St. Louis, MO) with a mobile phase flow of 500 lL/min and solvents A: 60 : 40 water : methanol and B: 60 : 40 acetonitrile : methanol with 0.1% formic acid in A and B. The gradient was 0 ? 2 min 40% B, 2 ? 10 min increase to 55% B, 10 ? 17 min further increase to 90% B, then 95% B hold for 3 min before return to initial conditions and column equilibration for 4 min. For detection, positive mode atmospheric pressure chemical ionization was used and m/z transitions of 301 ? 205 for 13-cis-retinoic acid and all-transretinoic acid, 315 ? 159 for 4-oxo-13-cis-retinoic acid, 306 ? 116 for 13-cis-retinoic acid-d5 and all-trans-retinoic acid-d5, and 300 ? 226 for 4-oxo-all-trans-retinoic acid-d3 were monitored for quantification. All data were analyzed using Analyst software (AB Sciex, Foster City, CA). The intraand interassay coefficients of variation were between 2 and 8%, and the lower limit of quantitation was 2 nM for 13-cisretinoic acid and all-trans-retinoic acid and 8 nM for 4-oxo-13-cis-retinoic acid.
Statistical analysis
Due to the variability of single measurements of sperm counts, for analysis of the change in total motile sperm count (the primary end point), the three pre-treatment semen samples were averaged for the 'baseline' value and the three semen samples from treatment week 16, treatment week 20, and follow-up week 4 were averaged for the 'end-of-treatment' value. For the three men who discontinued isotretinoin therapy early, data from the last three available sperm samples were carried forward and used in the analysis. Secondary end points included sperm concentration, sperm motility, and sperm morphology, as well as changes in laboratory measures, serum and semen retinoic acid concentrations, mood effects, and other side effects. Inclusion of nineteen men was predicted to confer an 80% power to detect a 33% increase in sperm concentration between baseline and the end of treatment, allowing for a dropout rate of 10% at an alpha of 0.05.
Baseline and end-of-treatment sperm parameters were compared using Wilcoxon sign-rank tests due to non-normality. For analysis of laboratory assessments, retinoic acid concentrations and questionnaire data, a paired t-test was used. For end points with repeated measures, an adjusted p-value of 0.01 was used to correct for multiple comparisons. In exploratory analyses, univariate and multivariate linear and logistic regression were performed to determine whether significant relationships between any patient characteristic, including age, weight, baseline spermatozoa or hormonal parameters or season and changes in sperm parameters or the likelihood of response, were present. All analyses were performed using STATA version 10.0 (College Park, TX, USA). For unadjusted comparisons, an alpha of 0.05 was considered significant.
RESULTS
Subjects
Twenty-seven subjects were screened, and nineteen were enrolled. Six men were ineligible due to sperm criteria, and two subjects elected not to participate for personal reasons. Nineteen men enrolled and started treatment. The mean (AESD) age was 35 AE 4.6 years of age, and the mean body mass index was 28 AE 4.9 kg/m 2 . Eighteen of these men were White, and one was Asian. Sixteen men completed all study procedures and three men discontinued treatment early, all after twelve weeks of treatment. Two of these men discontinued due to a pregnancy in their partner, and one man discontinued due to a perceived lack of efficacy.
Semen parameters
Overall, the median (25th, 75th) sperm concentration increased from 2.5 (0.1, 5.9) million/mL at baseline to 3.8 (2.1, 13.0) million/mL at the end of treatment (p = 0.006). Four subjects had a sperm concentration of greater than 15 million/mL at some point between week 16 of treatment and week four of follow-up, compared with no subject at baseline (p < 0.001). Sperm concentrations before, during, and after treatment for the 12 subjects who had a baseline total sperm count of greater than one million are depicted in Fig. 1A and for those with a baseline count of less than one million in Fig. 1B .
Median sperm motility did not significantly differ between baseline and treatment at any time point ( Figure S1 ). Due to low sperm counts in some subjects, sperm morphology was only available on ten subjects at baseline and thirteen subjects at week 20. Among these men, there was a trend toward improved sperm morphology with 0.5 (0, 3) percent strict normal spermatozoa at baseline compared with 1 (0, 5) percent at the end of treatment (p = 0.056) ( Figure S2 ).
The numbers of total motile spermatozoa before, during, and after treatment for all 19 men are depicted individually in Fig. 2A and B. Overall, the median (25th, 75th) total, motile sperm count per ejaculate increased from a baseline of 2 (0.04, 5.8) million spermatozoa to 2.7 (0.18, 10.9) million spermatozoa after 20 weeks of treatment (p = 0.004).
In the twelve men who began with an average total motile count between 1 and 10 million, the median baseline total motile sperm count increased from 5.6 (2.3, 7.5) million spermatozoa to 8.7 (2.2, 15) million spermatozoa (p < 0.001). Subject #12 increased from an average baseline total motile sperm count of 8.8 million spermatozoa to an average total motile sperm count of 56 million spermatozoa by the end of treatment.
In the seven men who began the study with a total motile count of less than one million, the total motile sperm count increased from 0.01 (0.0006, 0.12) million spermatozoa to 0.13 (0.05, 1.2) million spermatozoa (p = 0.04) at the end of treatment. One of these men, subject #13, increased from a baseline of 0.2 million spermatozoa to a peak of 26 million spermatozoa after 16 weeks of treatment.
The percent change in total motile sperm count with treatment is depicted in Fig. 2C . Overall, the median (25th, 75th) percent change in all 19 men was a 122 (10, 1266) percent increase.
Pregnancies
Six pregnancies and five births occurred in the female partners of men enrolled in the study. Three of the six pregnancies were spontaneous, and three were the product of ICSI. Four of the six pregnancies, including all three spontaneous pregnancies, were observed in men with improvements in sperm concentrations with isotretinoin therapy. Two of the three men (subjects #5 & #8) who fathered spontaneous pregnancies discontinued isotretinoin use when pregnancy was identified after 12 weeks of treatment. The third subject with a spontaneous pregnancy (subject #12) fathered twins after approximately 16 weeks of therapy. There was one miscarriage in the partner of subject who had become pregnant via ICSI. All six offspring from the five pregnancies appeared normal at birth without identifiable birth defects and continue to do well.
Serum and semen 13-cis-retinoic acid
The average serum 13-cis-retinoic acid (isotretinoin) and alltrans-retinoic acid concentrations before, during, and following treatment are shown in Fig. 3A and B. The mean (AESD) serum 13-cis-retinoic acid concentrations during treatment was 693 AE 201 nM, which was more than one hundred times higher than the baseline measurement of 6.7 AE 2.3 nM (p < 0.0001). In contrast, the average all-trans-retinoic acid concentration of 10.2 AE 2.1 nM was only 30-40% higher than the mean baseline values of 6.7 AE 2.3 nM (p < 0.001). Subjects also had marked increases in the 13-cis-retinoic acid metabolite serum 13-oxocis-retinoic acid during treatment which increased from 28 AE 7.5 nM at baseline to an average of 5418 AE 1710 nM during treatment (p < 0.0001).
Seminal plasma 13-cis-retinoic acid concentrations were undetectable at baseline and after treatment. During treatment, the average seminal 13-cis-retinoic acid concentration was 9.6 AE 2.4 nM. The highest measurable value in any subject at any time point was 22 nM. Seminal all-trans-retinoic acid concentrations were undetectable in any subject at baseline and after treatment. During treatment, only seven of 122 semen samples had a detectable concentration of all-trans-retinoic acid. These concentrations ranged from a 2.4 to 3.1 nM.
Adverse events
There were 59 adverse effects reported by fifteen different subjects during treatment (see Table S1 ). A significant increase in mean fasting serum triglycerides and a significant decrease in mean serum HDL were noted during treatment (Table 1) . There were no symptoms or clinical events attributable to these changes in serum lipids. Lastly, no subject complained of worsening mood during treatment, and there were no instances of depression during treatment. Figure 1 Sperm concentration (medians, interquartile ranges) before, during, and after treatment with isotretinoin for twenty weeks. (A) depicts the twelve men with a baseline total motile sperm count of greater than one million, and (B) depicts the seven men with fewer than one million total, motile spermatozoa at baseline. Note the log scale of the y-axis of B. *p < 0.05 compared with baseline.
1118 Andrology, 2017 Andrology, , 5, 1115 Andrology, -1123 Factors associated with isotretinoin response Using univariate and multivariate linear and logistic regression, no demographic, hormonal, spermatozoa, temporal, or pharmacokinetic parameter could be identified that was associated with a significantly greater likelihood of responding to isotretinoin therapy, either in terms of improvements in sperm production or the chance of pregnancy.
Effect of calcitriol
The administration of calcitriol to subjects eleven through nineteen had no apparent effect on any sperm parameter or laboratory measure compared to the men who did not receive calcitriol.
DISCUSSION
In this manuscript, we present data from the first study to test the hypothesis that men with infertility from OA will exhibit increased sperm counts from treatment with 13-cis-retinoic acid (isotretinoin). Vitamin A was first studied as a treatment for male infertility from reduced sperm counts in the 1950s, but no benefit was found (Horne & Maddock, 1952; Kapadia & Phadke, 1959) . However, it was not until the 1980s that it was appreciated 1,000,000 1 2 3 4 5 6 7 8 9 10 1112 13 1415 16171819
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12 men with baseline >1 million 7 men with baseline <1 million Figure 2 Total motile sperm counts for each subject. The baseline and treatment values are an average of three semen samples prior to or during treatment. The follow-up values are an average of the two semen samples obtained 12 and 24 weeks following treatment. (A) depicts the twelve men with a baseline total motile sperm count of greater than one million, and B depicts the seven men with fewer than one million total, motile spermatozoa at baseline (B). (C) shows the percent change in total motile spermatozoa between baseline and the end of treatment. Note the log scale of the y-axis of B. * no follow-up sample; ** follow-up sample with total, motile sperm count of zero.
that the active metabolite of vitamin A, retinoic acid, was the molecule required for sperm production. Indeed, vitamin A therapy could not improve spermatogenesis in men whose intratesticular retinoic acid concentrations were low due to impaired biosynthesis of retinoic acid. As a result, we have focused our work treating men with infertility on retinoic acid, rather than vitamin A. There are two notable features of the data from this study. Firstly, our results are similar to those seen in normal men receiving isotretinoin therapy for the treatment of acne. Both fertile and infertile men experienced increased sperm counts, but no changes in sperm motility (Vogt & Ewers, 1985; Torok et al., 1987; Hoting et al., 1992; C ß inar et al., 2016) . Secondly, significant increases in sperm production in men receiving isotretinoin are not apparent until after twelve weeks of treatment. This observation is consistent with the role of retinoic acid in spermatogonial differentiation and the 9-to 12-week maturation period for spermatozoa in humans (Heller & Clermont, 1963; Misell et al., 2006) . As a result, longer periods of isotretinoin treatment may be of benefit to men with infertility. Lastly, the elevations in sperm concentrations appear to persist for several weeks after drug discontinuation, presumably as the germ cells stimulated to differentiate by retinoic acid complete maturation within the seminiferous tubules.
Mechanism of isotretinoin action
During spermatogenesis, pulses of retinoic acid have been shown to move along the seminiferous tubules coincident with the spermatogenic wave . In mice, during stages VII to IX, the endogenous retinoic acid pulse plays a role in several crucial processes, including spermiation, tight junction remodeling, and the transition of undifferentiated spermatogonia into differentiating spermatogonia, possibly via expression of Sall4a, Stra8, and/or Rec8 (Koubova et al., 2014; Gely-Pernot et al., 2015) .
Given what is known about endogenous retinoic acid's role in spermatogenesis, how does exogenously administered retinoic acid stimulate spermatogenesis in infertile men? Based on our earlier findings, we hypothesize that the biosynthesis of retinoic acid from vitamin A may be impaired in the men with infertility who responded to treatment with isotretinoin, possibly due to lower expression of ALDH1A. In contrast to most tissues, almost none of the retinoic acid in the testes comes from the circulation (Kurlandsky et al., 1995) , suggesting that intratesticular retinoic acid is all produced in situ. Previously, our group demonstrated that the biosynthesis of retinoic acid in the human testes correlates strongly with the concentrations of the ALDH1A enzymes , which are reduced in the testes of men with infertility . It has been postulated that the testes are protected from circulating retinoic acid by CYP26, the enzyme that metabolizes retinoic acid to inactive metabolites, in the peritubular myoid and Sertoli cells (Wu et al., 2008) , and that this serves, in part, to prevent the premature initiation of spermatogenesis prior to puberty (Bowles et al., 2006) .
Our study, using pharmacological doses of retinoic acid, resulted in roughly 100-fold increases in circulating 13-cis-retinoic acid concentrations, which likely overwhelmed the ability of the peritubular myoid and Sertoli cells to prevent exposure of the tubules to circulating retinoic acid. In some men, this may have addressed their increased their intratesticular retinoic acid concentration and stimulated sperm production. Importantly, isotretinoin is not as good a substrate for CYP26, the enzyme that metabolizes retinoic acid, as all-trans-retinoic acid (Topletz et al., 2011) , possibly making it a better drug for this indication. In any case, the exact mechanism and pharmaceutical means by which retinoic acid supports spermatogenesis will be the subject of future study.
Safety of isotretinoin therapy
Subjects in our study had the expected side effects from isotretinoin, but generally tolerated the treatment well. Isotretinoin is teratogenic and should never be administered to women at risk of pregnancy without the use of adequate contraception. Importantly, despite many years of use, there is no evidence to suggest teratogenic effect in the children of women who conceived while Figure 3 Serum 13-cis-retinoic acid (A) and all-trans-retinoic acid (B) concentrations before, during, and after treatment. All values are means AE SD. *p < 0.05, **p < 0.01 compared with baseline.
1120 Andrology, 2017, 5, 1115-1123 their husbands were taking isotretinoin. As a result, men using isotretinoin or other retinoids are not required to use condoms for intercourse. This is likely due to the observation that retinoid exposure via semen to female partners of men taking retinoids appears to be so low that it does not alter endogenous retinoid concentrations (Schmitt-Hoffman et al., 2011) . In our study, we found isotretinoin concentrations in the semen during treatment were all below 25 nM. At this concentration, and assuming complete absorption across the vaginal mucosa, an ejaculate volume of 5 cc would expose a pregnant female partner to approximately 35 nanograms of 13-cis-retinoic acid. This exposure is several orders of magnitude below the chronic 0.5-1.0 mg/kg dose range associated with teratogenicity in humans (Lammer et al., 1985; Rosa, 1987) . As a result, exposure of a pregnant female partner to isotretinoin via her sexual partner's semen appears to be negligible.
Variability of response
A weakness of the study is that we were unable to identify a correlate or biomarker of responsiveness to isotretinoin therapy. One hypothesis would be that men with low baseline concentration or 13-cis-retinoic acid would be more likely to respond to therapy; however, we did not obtain testicular biopsies at baseline in this study. A biomarker that could predict response would be of significant clinical utility in selecting the most appropriate men with infertility for treatment with isotretinoin. Another weakness of the study was our small sample size of nineteen men. As a result, our study was likely underpowered to observe significant changes in end points such as morphology. Future studies of isotretinoin in infertile men will need to be larger to determine whether morphology is improved with therapy.
Implications for the treatment of male infertility
Because of its widespread use for acne for over 35 years, isotretinoin is widely available. However, before isotretinoin can be incorporated into male infertility treatment algorithms, additional study of its efficacy and safety will be required, and its use outside of controlled, clinical trials is premature. Notably, we choose a dose in the low range of clinical use (approximately 0.5 mg/kg daily) as doses of up to 2 mg/kg daily are sometimes used for the treatment of acne (Del Rosso, 2012) and may be of use for men with infertility. In addition, it is possible longer periods of treatment may result in improved outcomes. Lastly, because sperm parameters are a poor proxy for fertility, live birth rate should be the primary outcome in future studies of isotretinoin therapy for couples with infertility associated with OA. If larger, randomized, placebo-controlled trials demonstrate safety and efficacy, isotretinoin therapy might allow couples in whom the male partner has infertility from OA to conceive spontaneously or use techniques such as intrauterine insemination rather than ICSI. Alternatively, isotretinoin therapy might allow men who do not currently qualify for ICSI the opportunity to try these procedures to achieve fertility.
Summary
Our pilot study suggests that a significant subset of men with oligoasthenozoospermia respond to isotretinoin therapy with increased sperm output. Additional study of isotretinoin for the treatment of men with infertility from reduced sperm production is warranted.
